

Guido Forni: Pubblicazioni più importanti

LIBRI

Trần Thanh Loan, Trần Đình Bình, Piero Musiani, Guido Forni, Miễn Dịch Học Cơ Bản, Huè University Press, Huè, Viet Nam 2019 (in press)

Musiani P and Forni G, 2010 Basic Immunology, <https://issuu.com/guidoforni5/docs/2019i>

Musiani P and Forni G, Basic Immunology, Piccin; Padua, 2017.

Quaglino E, Cavallo F and Forni G, Le difese immunitarie, Piccin, Padova, 2010

Forni G, Foà R, Santoni A, Frati L eds, Cytokine-induced tumor immunogenicity. Academic Press, London, 1994.

NATURE JOURNALS (5)

Forni G, Bindoni M, Santoni A, Belluardo N, Marchese AE, Giovarelli M. Radiofrequency destruction of the tuberoinfundibular region of hypothalamus permanently abrogates NK cell activity in mice. *Nature* 1983;306:181-184

Schramek D, Meixner A, Kotsinas A, Wada T, Sigl V, Zwick RH, Pospisilik A, Neely GG, Forni G, Serrano M, Gorgoulis VG, Penninger JM, The stress kinase MKK7 functions as tumor suppressor in breast and lung cancer by stabilizing p53, *Nature Genetics* 2011;43:212-219

Chiarle R, Martinengo C, Mastini C, Ambrogio C, D'Escamard V, Forni G, Inghirami G, The anaplastic lymphoma kinase is an effective oncoantigen for lymphoma vaccination, *Nature Med* 2008;14:676-680

Cavallo F, Calogero RA, Forni G, Are oncoantigens suitable targets for antitumor therapy? *Nature Rev Cancer* 2007;7:707-712

Lollini P-L, Cavallo F, Nanni P, Forni G, Vaccines for cancer prevention, *Nature Rev Cancer* 2006;6:204-216
**Commentary by Olivera J Finn, Tumor immunology top 10 list, Immunol. Rev. 2008;222:5-8*

CELL JOURNALS (2)

Pellicci G, Lanfrancone L, Grignani F, McGlade J, Cavallo F, Forni G, Nicoletti I, Grignani F, Pawson T, Pellicci PG. A novel transforming protein (SHC) with an SH2 domain is implicated in mitogenic signal transduction. *Cell* 1992;70:93-104

Hüsemann Y, Geigl JB, Schubert F, Musiani P, Meyer M, Burghart E, Forni G, Eils R, Fehm T, Riethmüller G, and Klein CA, Systemic spread is an early step in breast cancer, *Cancer Cell* 2008;13:58-68
**Journal cover*

SCIENCE JOURNALS (2)

Landolfo S, Cofano F, Giovarelli M, Prat M, Cavallo G, Forni G. Inhibition of interferon-gamma may suppress allograft reactivity by T lymphocytes in vitro and in vivo. *Science* 1985;229:176-9

Ciraolo E, Curcio C, Marone R, Marengo S, Iezzi M, Costa C, Gonella C, Rubinetto C, Caldarola S, Dastrù W, Silengo L, Altruda F, Turco E, Loreni F, Musiani P, Rommel C, Backer J.M., Forni G, Wymann M, Hirsch E., Key role of phosphoinositide 3-Kinase p110beta catalytic function in metabolism and cancer but not development, *Science Signalling* 2008;1:1-12

**Journal cover*

JOURNAL OF CLINICAL INVESTIGATION (2)

Quaglino E, Rolla S, Iezzi M, Spadaro M, Musiani P, De Giovanni C, Lollini PL, Lanzardo S, Forni G, Sanges R, Crispi S, De Luca P, Calogero R, Cavallo F. Concordant morphologic and gene expression data show that a vaccine halts HER-2/neu preneoplastic lesions. *J Clin Invest* 2004;113:709-717

Curcio C, Di Carlo E, Clynes R, Smyth MJ, Boggio K, Quaglino E, Spadaro M, Colombo MP, Amici A, Lollini PL, Musiani P, Forni G, Nonredundant roles of antibody, cytokines and perforin for the immune eradication of established Her-2/neu carcinomas *J Clin Invest* 2003;111:1161-70

**Commentary by Glenn Dranoff, Coordinated tumor immunity, J. Clin. Invest. 2003;111:1116-1118*

THE JOURNAL OF EXPERIMENTAL MEDICINE (5)

Nanni P, Nicoletti G, De Giovanni C, Landuzzi L, Di Carlo E, Cavallo F, Pupa SM, Rossi I, Colombo MP, Ricci C, Astolfi A, Musiani P, Forni G, Lollini PL. Combined allogeneic tumor cell vaccination and systemic interleukin 12 prevents mammary carcinogenesis in HER-2/neu transgenic mice. *J Exp Med* 2001;194:1195-1205.

**Commentary by Kristine Novak Nature Rev Cancer, 2001;1:175*

Boggio K, Nicoletti G, Di Carlo E, Cavallo F, Landuzzi L, Melani C, Giovarelli M, Rossi I, Nanni P, De Giovanni C, Bouchard P, Wolf S, Modesti A, Musiani P, Lollini PL, Colombo MP, Forni G. Interleukin 12-mediated prevention of spontaneous mammary adenocarcinomas in two lines of Her-2/neu transgenic mice, *J Exp Med* 1998;188:589-596.

Scala G, Quinto I, Ruocco MR, Arcucci A, Mallardo M, Caretto P, Forni G, Venuta S. Expression of an exogenous interleukin 6 gene in human Epstein Barr virus B cells confers growth advantage and in vivo tumorigenicity. *J Exp Med* 1990;172:61-68.

Boraschi D, Nencioni L, Villa L, Censini S, Bossu P, Ghiara P, Presentini R, Perin F, Frasca D, Doria G, Forni G, Tagliabue A. In vivo stimulation and restoration of the immune response by the noninflammatory fragment 163-171 of human interleukin 1 beta. *J Exp Med* 1988;168:675-586

Forni G, Shevach EM, Green I. Mutant lines of guinea pig L2C leukemia. I. Deletion of Ia alloantigens is associated with a loss in immunogenicity of tumor-associated transplantation antigens. *J Exp Med* 1976;143:1067-1072

JOURNAL OF THE NATIONAL CANCER INSTITUTE (5)

Cavallo F, Signorelli P, Giovarelli M, Musiani P, Modesti A, Brunda MJ, Colombo MP, Forni G. Antitumor efficacy of adenocarcinoma cells engineered to produce interleukin 12 (IL-12) or other cytokines compared with exogenous IL-12. *J Natl Cancer Inst.* 1997;89:1049-1058.

Cignetti A, Guarini A, Carbone A, Forni M, Cronin K, Forni G, Gansbacher B, Foa R. Transduction of the IL2 gene into human acute leukemia cells: induction of tumor rejection without modifying cell proliferation and IL2 receptor expression. *J Natl Cancer Inst.* 1994;86:785-791.

Forni G, Cerruti Sola S, Giovarelli M, Santoni A, Martinetto P, Vietti D. Effect of prolonged administration of low doses of dietary retinoids on cell-mediated immunity and the growth of transplantable tumors in mice. *J Natl Cancer Inst.* 1986;76:527-532

Forni G, Serrati G, Giordano L, Giovarelli M, Rendine S, Landolfo S. Interaction of H-2 and non-H-2 genes in spontaneous resistance to adenocarcinoma ADK-1t in F1 mice. *J Natl Cancer Inst.* 1980;65:651-655

Whang-Peng J, Lee EC, Forni G, Green I. Mutant lines of guinea pig L2C leukemia. II. Comparative cytogenetic studies and banding analyses of normal and leukemic karyotypes. *J Natl Cancer Inst.* 1976;57:897-905

CURRENT JOURNALS (4)

Lollini P-L, Nicoletti G, Landuzzi L, Cavallo F, Forni G, De Giovanni C, and Nanni P, Vaccines and Other Immunological Approaches for Cancer Immunoprevention, *Curr Drug Targets*, 2011;12: 1957-1973

Finn OJ, Forni G. Prophylactic cancer vaccines. *Curr Opin Immunol.* 2002;14:172-7

Bellomo N, Forni G, Complex Multicellular Systems and Immune Competition: New Paradigms Looking for a Mathematical Theory, *Curr Topics Dev Biol*, 2008;81:485-502 5.7

Mastini C, Becker PD, Iezzi M, Curcio C, Musiani P, Forni G, Cavallo F, Guzman CA, Intramammary application of non-methylated-CpG oligodeoxynucleotides (CpG) inhibits both local and systemic mammary carcinogenesis in female BALB/c Her-2/neu transgenic mice, *Curr Cancer Drug Targets* 2008;8:230-242

BLOOD (4)

Melani C, Chiodoni C, Forni G, and Colombo MP, Myeloid cell expansion elicited by the progression of spontaneous mammary carcinomas in c-erbB-2 transgenic BALB/c mice suppresses immune reactivity, Blood 2003;102:2138-2145

Di Carlo E, Forni G, Lollini P, Colombo MP, Modesti A, Musiani P. The intriguing role of polymorphonuclear neutrophils in antitumor reactions. Blood 2001;97:339-45.

Cavallo F, Forni M, Riccardi C, Soleti A, Di Pierro F, Forni G. Growth and spread of human malignant T lymphoblasts in immunosuppressed nude mice: a model for meningeal leukemia. Blood. 1992;80:1279-1283

Foa R, Giovarelli M, Jemma C, Fierro MT, Lusso P, Ferrando ML, Lauria F, Forni G. Interleukin 2 (IL 2) and interferon-gamma production by T lymphocytes from patients with B-chronic lymphocytic leukemia: evidence that normally released IL 2 is absorbed by the neoplastic B cell population. Blood 1985;66:614-619

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES (2)

Holmgren L, Ambrosino E, Birot O, Tullus C, Veitonmäki N, Carlson L-M, Musiani P, Iezzi M, Curcio C, Forni G, Cavallo F and Kiessling R, A DNA vaccine targeting angiominin inhibits angiogenesis and suppresses tumor growth, Proc Natl Acad Sci USA 2006;103:9208-9213

Hayakawa Y, Rovero S, Forni G, Smyth M.J., β -Galactosylceramide (KRN7000) suppression of chemical- and oncogene-dependent carcinogenesis. Proc. Natl. Acad. Sci. USA 2000;100:9464-9469

CANCER METASTASIS REVIEW (2)

Colombo MP, Forni G. Immunotherapy. I: Cytokine gene transfer strategies. Cancer Metastasis Rev. 1997;16:421-432

Forni G, Fujiwara H, Martino F, Hamaoka T, Jemma C, Caretto P, Giovarelli M. Helper strategy in tumor immunology: expansion of helper lymphocytes and utilization of helper lymphokines for experimental and clinical immunotherapy. Cancer Metastasis Rev. 1988;7:289-309.

BIOCHIMICA ET BIOPHYSICA ACTA (BBA)

Forni G, Giovarelli M, Santoni A, Modesti A, Forni M. Tumour inhibition by interleukin-2 at the tumour/host interface. Biochim Biophys Acta 1986;865:307-327

LEUKEMIA

Fierro MT, Liao XS, Lusso P, Bonferroni M, Matera L, Cesano A, Lista P, Arione R, Forni G, Foa R. In vitro and in vivo susceptibility of human leukemic cells to lymphokine activated killer activity. *Leukemia*. 1988;2:50-54.

EMBO JOURNAL

Di Stefano P, Damiano L, Cabodi S, Aramu S, Tordella L, Praduroux A, Piva R, Cavallo F, Forni G, Silengo L, Tarone G, Turco E, Defilippi P, p140Cap protein suppresses tumour cell properties, regulating Csk and Src kinase activity, *EMBO J* 2007;26:2843-2855

TRENDS JOURNALS (4)

Lollini P-L, Forni G, Cancer immunoprevention: Tracking down persistent tumor antigens, *Trends Immunol*, 2003;24:62-66

Lollini PL, Forni G. Specific and nonspecific immunity in the prevention of spontaneous tumours. *Immunol Today*. 1999;20:347-50.

Musiani P, Modesti A, Giovarelli M, Cavallo F, Colombo MP, Lollini PL, Forni G. Cytokines, tumour-cell death and immunogenicity: a question of choice. *Immunol Today*. 1997;18:32-6

Colombo MP, Forni G. Cytokine gene transfer in tumor inhibition and tumor therapy: where are we now? *Immunol Today*. 1994;15:48-51.

ADVANCES IN IMMUNOLOGY

Cavallo F, Offringa R, van der Burg SH, Forni G, Melief CJ. Vaccination for treatment and prevention of cancer in animal models. *Adv Immunol* 2006;90:175-213

CANCER RESEARCH JOURNALS (29)

Quaglino E, Mastini C, Amici A, Marchini C, Iezzi M, Lanzardo S, De Giovanni C, Montani M, Lollini PL, Masucci G, Forni G, Cavallo F. A better immune reaction to ErbB-2 tumors is elicited in mice by DNA vaccines encoding rat/human chimeric proteins. *Cancer Res*, 2010;70:2604-2612, 2010

Steel JC, Ramlogan CA, Yu P, Sakai Y, Forni G, Waldmann TA, Morris JC, Interleukin-15 and its Receptor Augment Dendritic Cell Vaccination Against the neu Oncogene Through the Induction of Antibodies Partially Independent of CD4- help, *Cancer Res* 2010;70:1072-1081

Tegerstedt K, Lindencrona JA, Curcio C, Andreasson K, Tullus C, Forni G, Dalianis T, Kiessling R, Ramqvist T. A single vaccination with polyomavirus VP1/VP2Her2 virus-like particles prevents outgrowth of HER-2/neu-expressing tumors. *Cancer Res*. 2005;65:5953-7

Park JM, Terabe M, Steel JC, Forni G, Sakai Y, Morris JC, Berzofsky JA, Therapy of advanced established murine breast cancer with a recombinant adenoviral ErbB-2/neu vaccine, *Cancer Res*, 2008;68:1979-1987

Spadaro M, Curcio C, Varadhachary A, Cavallo F, Engelmayr J, Blezinger P, Pericle F, Forni G, Requirement for IFN-g, CD8+ T lymphocytes and NKT cells in Talactoferrin-induced inhibition of neu+ tumors, *Cancer Res* 2007;67:6425-6432

Nava-Parada, P., Forni, G., Knutson, K. L., Pease, L. R., Celis, E. Peptide vaccine given with a Toll-like receptor agonist is effective for the treatment and prevention of spontaneous breast tumors, *Cancer Res* 2007;67:1326-1334

Ambrosino E, Spadaro M, Iezzi M, Curcio C, Forni G, Musiani P, Wei WZ, Cavallo F. Immunosurveillance of ErbB2 carcinogenesis in transgenic mice is concealed by a dominant regulatory T-cell self-tolerance. *Cancer Res* 2006;66:7734-7740

Cabodi S, Tinnirello A, Di Stefano P, Ambrosino E, Castellano I, Sapino A, Arisio R, Cavallo F, Forni G, Glukhova M, Silengo L, Altruda F, Turco E, Tarone G, Defilippi P, p130Cas as a new regulator of mammary gland development and of HER2-Neu-dependent tumorigenesis, *Cancer Res* 2006;66:4672-4680

Tegerstedt K, Lindencrona JA, Curcio C, Andreasson K, Tullus C, Forni G, Dalianis T, Kiessling R, Ramqvist T, A single vaccination with polyomavirus VP1/VP2Her2 virus-like particles (VLPs) prevents outgrowth of Her2/neu expressing tumors, *Cancer Res* 2005;65:5953-5957

Croci S, Nicoletti G, Landuzzi L, De Giovanni C., Astolfi A., Marini C, Di Carlo E, Musiani P, Forni G, Nanni P, Lollini P-L, Immunological prevention of a multigene cancer syndrome, *Cancer Res* 2004;64:8428-8434

Sakai Y, Morrison BJ, Burke JD, Park J-M, Terabe M, Janik JE, Forni G, Berzofsky JA, Morris JC, Vaccination by Genetically Modified Dendritic Cells Expressing a Truncated neu Oncogene Prevents Development of Breast Cancer in Transgenic Mice, *Cancer Res* 2004;64:8022-8028

Quaglino E, Iezzi M, Mastini C, Amici A, Pericle F, Di Carlo E, Pupa SM, De Giovanni C, Spadaro M, Curcio C, Lollini P-L, Musiani P, Forni G, Cavallo F, Electroporated DNA vaccine clears away multifocal mammary carcinomas in Her-2/neu transgenic mice, *Cancer Res* 2004;64:2858-2864

Cappello P, Triebel F, Iezzi M, Caorsi C, Quaglino E, Lollini P-L, Amici A, Di Carlo E, Musiani P, Giovarelli M, Forni G, LAG-3 enables DNA vaccination to persistently prevent mammary carcinogenesis in HER-2/neu transgenic BALB/c mice, *Cancer Res* 2003;63:2518-2525

Cavallo F, Quaglino E, Cifaldi L, Di Carlo E, Andre A, Bernabei P, Musiani P, Forni G, Calogero RA. Interleukin 12-activated lymphocytes influence tumor genetic programs. *Cancer Res*. 2001;61:3518-3523

Cifaldi L, Quaglino E, Di Carlo E, Musiani P, Spadaro M, Lollini PL, Wolf S, Boggio K, Forni G, Cavallo F. A light, nontoxic interleukin 12 protocol inhibits HER-2/neu mammary carcinogenesis in BALB/c transgenic mice with established hyperplasia. *Cancer Res.* 2001;61:2809-12.

Forni G, Lollini PL, Musiani P, Colombo MP. Immunoprevention of cancer: is the time ripe? *Cancer Res.* 2000;60:2571-5.

Boggio K, Di Carlo E, Rovero S, Cavallo F, Quaglino E, Lollini PL, Nanni P, Nicoletti G, Wolf S, Musiani P, Forni G. Ability of systemic interleukin-12 to hamper progressive stages of mammary carcinogenesis in HER2/neu transgenic mice. *Cancer Res.* 2000;60:359-64

Cavallo F, Di Carlo E, Butera M, Verrua R, Colombo MP, Musiani P, Forni G. Immune events associated with the cure of established tumors and spontaneous metastases by local and systemic interleukin 12. *Cancer Res.* 1999;59:414-21.

Vagliani M, Rodolfo M, Cavallo F, Parenza M, Melani C, Parmiani G, Forni G, Colombo MP. Interleukin 12 potentiates the curative effect of a vaccine based on interleukin 2-transduced tumor cells. *Cancer Res.* 1996;56:467-70

Allione A, Consalvo M, Nanni P, Lollini PL, Cavallo F, Giovarelli M, Forni M, Gulino A, Colombo MP, Dellabona P, Forni G. Immunizing and curative potential of replicating and nonreplicating murine mammary adenocarcinoma cells engineered with interleukin (IL)-2, IL-4, IL-6, IL-7, IL-10, tumor necrosis factor alpha, granulocyte-macrophage colony-stimulating factor, and gamma-interferon gene or admixed with conventional adjuvants. *Cancer Res.* 1994;54:6022-6

Cavallo F, Di Pierro F, Giovarelli M, Gulino A, Vacca A, Stoppacciaro A, Forni M, Modesti A, Forni G. Protective and curative potential of vaccination with interleukin-2-gene-transfected cells from a spontaneous mouse mammary adenocarcinoma. *Cancer Res.* 1993;53:5067-70

Colombo MP, Modesti A, Parmiani G, Forni G. Local cytokine availability elicits tumor rejection and systemic immunity through granulocyte-T-lymphocyte cross-talk. *Cancer Res.* 1992;52:4853-4857

Giovarelli M, Padula E, Ugazio G, Forni G, Cavallo G. Strain- and sex-linked effects of dietary polyunsaturated fatty acids on tumor growth and immune functions in mice. *Cancer Res.* 1980;40:3745-9

Varesio L, Giovarelli M, Landolfo S, Forni G. Suppression of proliferative response and lymphokine production during the progression of a spontaneous tumor. *Cancer Res.* 1979;39:4983-8

Varesio L, Cappuccinelli P, Forni G. Inhibition of replication of virus-transformed fibroblasts by antibodies to RNA. *Cancer Res.* 1975;35:3558-65

Sloots A, Mastini C, Rohrbach F, Weth R, Curcio C, Jäger E, Forni G, Cavallo F, and Wels W.S., DNA vaccines targeting tumor antigens to antigen presenting cells in vivo induce protective anti-tumor immunity and delay onset of Her2/neu-driven mammary carcinoma, *Clin Cancer Res* 2008, 14:6933-6943

Spadaro M, Ambrosino E, Iezzi M, Di Carlo E, Sacchetti P, Curcio C, Amici A, Wei WZ, Musiani P, Lollini PL, Forni G, F Cavallo, Cure of mammary carcinomas in Her-2 transgenic mice through sequential stimulation of innate (neo-adjuvant il12) and adaptive (DNA Vaccine Electroporation) immunity, *Clin Cancer Res* 2005;11:1941-1952

Di Carlo E, Rovero S, Boggio K, Quaglino E, Amici A, Smorlesi A, Forni G, Musiani P. Inhibition of mammary carcinogenesis by systemic interleukin 12 or p185neu DNA vaccination in Her-2/neu transgenic BALB/c mice. *Clin Cancer Res.* 2001;7:830s-837s.

Berta GN, Sprio AE, Iezzi M, Spadaro M, Cappia S, Salamone P, Di Scipio F, Mognetti B, Papotti M, Musiani P, Forni G, Cavallo F, A DNA vaccine against ERBB2 impairs chemical carcinogenesis in random-bred hamsters, *Cancer Prev Res* 2011; 4:994-1001

JOURNAL OF PATHOLOGY (4)

Curcio C, Pannellini T, Lanzardo S, Forni G, Musiani P, Anton I. WIP null mice display a progressive immunological disorder that resembles Wiskott-Aldrich syndrome. *J Pathol* 2007;211:67-75

Di Carlo E, Cappello P, Sorrentino C, D'Antuono T, Pellicciotta A, Giovarelli M, Forni G, Musiani P, Triebel F, Immunological mechanisms elicited at the tumour site by lymphocyte activation gene-3 (LAG-3) versus IL-12: sharing a common Th1 anti-tumour immune pathway, *J Pathol* 2005;205:82-91

Di Carlo E, Modesti A, Coletti A, Colombo MP, Giovarelli M, Forni G, Diodoro MG, Musiani P. Interaction between endothelial cells and the secreted cytokine drives the fate of an IL4- or an IL5-transduced tumour. *J Pathol.* 1998;186:390-7.

Scarpa S, Giuffrida A, Palumbo C, Vasaturo F, Signorelli P, Forni G, Modesti M, Ferrantini M, Belardelli F, Musiani P, Modesti A. Extracellular matrix remodelling in a murine mammary adenocarcinoma transfected with the interferon-alpha 1 gene. *J Pathol.* 1997;81:116-23.

FASEB JOURNAL (2)

Cabodi S, Tinnirello A, Bisaro B, Tornillo G, Camacho-Leal MP, Forni G, Cojoca R, Iezzi M, Amici A, Montani M, Eva A, Di Stefano, Senthil K. Muthuswamy SK, Tarone G, Turco E, Defilippi P, p130Cas is an essential transducer element in ErbB2 transformation, *FASEB J.* 2010, 24:3796-808

Spadaro M, Caorsi C, Ceruti P, Varadhachary A, Forni G, Pericle F, Giovarelli M, Lactoferrin, a Major Defense Protein of innate immunity, is a novel maturation factor for human dendritic cells, FASEB J 2008, 22:2747-2757

AMERICAN JOURNAL OF PATHOLOGY

Astolfi A, Landuzzi L, Nicoletti G, De Giovanni, Croci S, Paladini A, Ferrini S, Iezzi M, Musiani P, Cavallo F, Forni G, Nanni P, Lollini P-L, Gene expression analysis of immune-mediated arrest of tumorigenesis in a transgenic mouse model of HER-2/neu-positive basal-like mammary carcinoma, Am J Pathol 2005;166:1205-1216

BREAST CANCER RESEARCH

Calogero RA, Cordero F, Forni G, Cavallo F, Inflammatory component of mammary carcinogenesis in Erbb2 transgenic mice, Breast Cancer Res 2007;9:211-217

THE JOURNAL OF IMMUNOLOGY (35)

Macagno M, Bandini S, Stramucci L, Quaglino E, Conti L, Balmas E, Smyth MJ, Lollini PL, Musiani P, Forni G, Iezzi M, Cavallo F. Multiple roles of perforin in hampering ERBB-2 (Her-2/neu) carcinogenesis in transgenic male mice. J Immunol. 2014;192:5434-41.

Rolla S, Ria F, Occhipinti S, Di Sante G, Iezzi M, Spadaro M, Nicolò C, Ambrosino E, Merighi IF, Musiani P, Forni G, Cavallo F, Erbb2 DNA vaccine combined with T regulatory cell deletion enhances antibody response and reveals latent low-avidity T cells. Potential and limits of its therapeutic efficacy, J Immunol, 2010;184:6124-6132

Porzia A, Lanzardo S, Citti A, Cavallo F, Forni G, Santoni A, Galandrini R, Paolini R, Attenuation of PI3K/AKT-mediated tumorigenic signals through PTEN activation by DNA vaccine-induced anti-ErbB2 antibodies, J. Immunol, 2010;184:4170-4177

Allen SD, Garrett JT, Rawale SV, Jones AL, Phillips G, Forni G, Morris JC, Oshima RG, Kaumaya PT. Peptide vaccines of the Her-2/neu dimerization loop are effective in inhibiting mammary tumor growth in vivo. J Immunol 2007;179:472-482

Garrett JT, Rawale S, Allen, SD, Phillips G, Forni G, Morris JC, Kaumaya PTP, Novel Engineered Trastuzumab Conformational Epitopes Demonstrate In Vitro and In Vivo Antitumor Properties against HER-2/neu, J. Immunol 2007;178:7120-7131

Rolla S, Nicolo C, Malinarich S, Orsini M, Forni G, Cavallo F, Ria F. Distinct and non-overlapping T cell receptor repertoires expanded by DNA vaccination in wild-type and HER-2 transgenic BALB/c mice. J Immunol 2006;177:7626-7633

Pannellini T, Spadaro M, Di Carlo E, Ambrosino E, Iezzi M, Amici A, Lollini P-L, Forni G, Cavallo F, Musiani P, Timely DNA vaccine combined with systemic IL-12 prevents parotid carcinomas before a dominant negative p53 makes their growth independent of HER-2/neu expression, *J. Immunol* 2006;176:7695-7703
**Journal cover*

Park JM, Terabe M, Sakai Y, Munasinghe J, Forni G, Morris JC, Berzofsky JA, Early Role of CD4+ Th1 cells and antibodies in HER-2 adenovirus-vaccine protection against autochthonous mammary carcinomas *J Immunol*, 2005;174:4228-4236

Nanni P, Landuzzi L, Nicoletti G, De Giovanni C, Rossi I, Croci S, Astolfi A, Iezzi M, Di Carlo E, Musiani P, Forni G, Lollini P-L, Immunoprevention of Mammary Carcinoma in HER-2/neu Transgenic Mice is ?- Interferon and B Cell Dependent, *J. Immunol* 2004;173:2288-2296

Strasly M, Cavallo F, Geuna M, Mitola S, Colombo MP, Forni G, Bussolino F. IL-12 inhibition of endothelial cell functions and angiogenesis depends on lymphocyte-endothelial cell cross-talk. *J Immunol*. 2001;166:3890-9

Rovero S, Amici A, Carlo ED, Bei R, Nanni P, Quaglino E, Porcedda P, Boggio K, Smorlesi A, Lollini PL, Landuzzi L, Colombo MP, Giovarelli M, Musiani P, Forni G. DNA vaccination against rat her-2/Neu p185 more effectively inhibits carcinogenesis than transplantable carcinomas in transgenic BALB/c mice. *J Immunol*. 2000;165:5133-42

Giovarelli M, Cappello P, Forni G, Salcedo T, Moore PA, LeFleur DW, Nardelli B, Carlo ED, Lollini PL, Ruben S, Ullrich S, Garotta G, Musiani P. Tumor rejection and immune memory elicited by locally released LEC chemokine are associated with an impressive recruitment of APCs, lymphocytes, and granulocytes. *J Immunol*. 2000;164:3200-6.

Rigamonti L, Ariotti S, Losana G, Gradini R, Russo MA, Jouanguy E, Casanova JL, Forni G, Novelli F. Surface expression of the IFN-gamma R2 chain is regulated by intracellular trafficking in human T lymphocytes. *J Immunol*. 2000;164:201-7

Giovarelli M, Musiani P, Garotta G, Ebner R, Di Carlo E, Kim Y, Cappello P, Rigamonti L, Bernabei P, Novelli F, Modesti A, Coletti A, Ferrie AK, Lollini PL, Ruben S, Salcedo T, Forni G. A "stealth effect": adenocarcinoma cells engineered to express TRAIL elude tumor-specific and allogeneic T cell reactions. *J Immunol*. 1999;163:4886-93.

Allione A, Bernabei P, Bosticardo M, Ariotti S, Forni G, Novelli F. Nitric oxide suppresses human T lymphocyte proliferation through IFN-gamma-dependent and IFN-gamma-independent induction of apoptosis. *J Immunol*. 1999;163:4182-91.

Allione A, Wells V, Forni G, Mallucci L, Novelli F. Beta-galactoside-binding protein (beta GBP) alters the cell cycle, up-regulates expression of the alpha- and beta-chains of the IFN-gamma receptor, and triggers IFN-gamma-mediated apoptosis of activated human T lymphocytes. *J Immunol.* 1998;161:2114-9.

Novelli F, D'Elios MM, Bernabei P, Ozmen L, Rigamonti L, Almerigogna F, Forni G, Del Prete G. Expression and role in apoptosis of the alpha- and beta-chains of the IFN-gamma receptor on human Th1 and Th2 clones. *J Immunol.* 1997;159:206-13.

Novelli F, Bernabei P, Ozmen L, Rigamonti L, Allione A, Pestka S, Garotta G, Forni G. Switching on of the proliferation or apoptosis of activated human T lymphocytes by IFN-gamma is correlated with the differential expression of the alpha- and beta-chains of its receptor. *J Immunol.* 1996;157:1935-43.

Giovarelli M, Musiani P, Modesti A, Dellabona P, Casorati G, Allione A, Consalvo M, Cavallo F, di Pierro F, De Giovanni C, and G. Forni. Local release of IL-10 by transfected mouse mammary adenocarcinoma cells does not suppress but enhances antitumor reaction and elicits a strong cytotoxic lymphocyte and antibody-dependent immune memory. *J Immunol.* 1995;155:3112-23

Consalvo M, Mullen CA, Modesti A, Musiani P, Allione A, Cavallo F, Giovarelli M, Forni G. 5-Fluorocytosine-induced eradication of murine adenocarcinomas engineered to express the cytosine deaminase suicide gene requires host immune competence and leaves an efficient memory. *J Immunol.* 1995;154:5302-12.

Pericle F, Giovarelli M, Colombo MP, Ferrari G, Musiani P, Modesti A, Cavallo F, Di Pierro F, Novelli F, Forni G. An efficient Th2-type memory follows CD8+ lymphocyte-driven and eosinophil-mediated rejection of a spontaneous mouse mammary adenocarcinoma engineered to release IL-4. *J Immunol.* 1994;153:5659-73

Ferrantini M, Giovarelli M, Modesti A, Musiani P, Modica A, Venditti M, Peretti E, Lollini PL, Nanni P, Forni G. IFN-alpha 1 gene expression into a metastatic murine adenocarcinoma (TS/A) results in CD8+ T cell-mediated tumor rejection and development of antitumor immunity. Comparative studies with IFN-gamma-producing TS/A cells. *J Immunol.* 1994, 153:4604-15.

Novelli F, Di Pierro F, Francia di Celle P, Bertini S, Affaticati P, Garotta G, Forni G. Environmental signals influencing expression of the IFN-gamma receptor on human T cells control whether IFN-gamma promotes proliferation or apoptosis. *J Immunol.* 1994;152:496-504.

Bosco MC, Musso T, Gusella GL, Giovarelli M, Forni M, Soleti A, Masuelli L, Modesti A, Forni G, Varesio L. Selective transformation of host lymphocytes in vivo by retrovirus-producing macrophages. *J Immunol.* 1993;150:278-89

Cavallo F, Giovarelli M, Gulino A, Vacca A, Stoppacciaro A, Modesti A, Forni G. Role of neutrophils and CD4+ T lymphocytes in the primary and memory response to nonimmunogenic murine mammary adenocarcinoma made immunogenic by IL-2 gene. *J Immunol.* 1992;149:3627-35

Novelli F, Giovarelli M, Reber-Liske R, Virgallita G, Garotta G, Forni G. Blockade of physiologically secreted IFN-gamma inhibits human T lymphocyte and natural killer cell activation. *J Immunol.* 1991;147:1445-52.

Bosco M, Giovarelli M, Forni M, Modesti A, Scarpa S, Masuelli L, Forni G. Low doses of IL-4 injected perilymphatically in tumor-bearing mice inhibit the growth of poorly and apparently nonimmunogenic tumors and induce a tumor-specific immune memory. *J Immunol.* 1990;145:3136-43.

Forni G, Musso T, Jemma C, Boraschi D, Tagliabue A, Giovarelli M. Lymphokine-activated tumor inhibition in mice. Ability of a nonapeptide of the human IL-1 beta to recruit anti-tumor reactivity in recipient mice. *J Immunol.* 1989 15;142:712-8

Giovarelli M, Santoni A, Jemma C, Musso T, Giuffrida AM, Cavallo G, Landolfo S, Forni G. Obligatory role of IFN-gamma in induction of lymphokine-activated and T lymphocyte killer activity, but not in boosting of natural cytotoxicity. *J Immunol.* 1988;141:2831-6.

Forni G, Giovarelli M, Santoni A, Modesti A, Forni M. Interleukin 2 activated tumor inhibition in vivo depends on the systemic involvement of host immunoreactivity. *J Immunol.* 1987;138:4033-41

Giovarelli M, Santoni A, Forni G. Alloantigen-activated lymphocytes from mice bearing a spontaneous "nonimmunogenic" adenocarcinoma inhibit its growth in vivo by recruiting host immunoreactivity. *J Immunol.* 1985;135:3596-603

Forni G, Giovarelli M, Santoni A. Lymphokine-activated tumor inhibition in vivo. I. The local administration of interleukin 2 triggers nonreactive lymphocytes from tumor-bearing mice to inhibit tumor growth. *J Immunol.* 1985;134:1305-11

Forni G, Giovarelli M. In vitro reeducated T helper cells from sarcoma-bearing mice inhibit sarcoma growth in vivo. *J Immunol.* 1984;132:527-33

Landolfo S, Martinotti MG, Martinetto P, Forni G. Natural cell-mediated cytotoxicity against *Trichomonas vaginalis* in the mouse. I. Tissue, strain, age distribution, and some characteristics of the effector cells. *J Immunol.* 1980;124:508-14

Thomas DW, Forni G, Shevach EM, Green I. The role of the macrophage as the stimulator cell in contact sensitivity. *J Immunol.* 1977;118:1677-8

Forni G, Green I. Heterologous sera: a target for in vitro cell-mediated cytotoxicity. *J Immunol.* 1976;116:1561-1565.

Forni G, Rhim JS, Pickeral S, Shevach EM, Green I. Antigenicity of carcinogen and viral induced sarcomas in inbred and random bred guinea pigs. *J Immunol.* 1975;115:204-210

ANNALS OF ONCOLOGY (2)

Nanni P, Forni G, Lollini PL. Cytokine gene therapy: hopes and pitfalls. *Ann Oncol.* 1999;10:261-6

Forni G, Parmiani G, Guarini A, Foa R. Gene transfer in tumor therapy. *Ann Oncol.* 1994;5:789-94

J CELLULAR AND MOLECULAR MEDICINE

Coscia M, Quaglino E, Iezzi M, Curcio C, Pantaleoni F, Riganti C, Holen I, Mönkkönen H, Boccadoro M, Forni G, Musiani P, Bosia A, Cavallo F, Massaia M. Zoledronic acid repolarizes tumor-associated macrophages and inhibits mammary carcinogenesis by targeting the mevalonate pathway. *J. Cell. Mol. Med.* 2010, 14:2803-2815

CANCER (2)

Cortesina G, De Stefani A, Giovarelli M, Barioglio MG, Cavallo GP, Jemma C, Forni G. Treatment of recurrent squamous cell carcinoma of the head and neck with low doses of interleukin-2 injected perilymphatically. *Cancer* 1988;62:2482-5

De Stefani A, Forni G, Ragona R, Cavallo G, Bussi M, Usai A, Badellino F, Cortesina G. Improved survival with perilymphatic interleukin 2 in patients with resectable squamous cell carcinoma of the oral cavity and oropharynx. *Cancer* 2002;95:90-7

INT J BIOCHEM CELL BIOL

Lanzardo S, Curcio C, Forni G, Anton IM. A role for WASP Interacting Protein, WIP, in fibroblast adhesion, spreading and migration. *Int J Biochem Cell Biol.* 2007;39:262-274

EUROPEAN JOURNAL OF IMMUNOLOGY (8)

Losana G, Rigamonti L, Borghi I, Assenzio B, Ariotti S, Jouanguy E, Altare, F, Forni G, Casanova JL, Novelli F. Requirement for both IL-12 and IFN-gamma signaling pathways in optimal IFN-gamma production by human T cells. *Eur J Immunol.* 2002;32:693-700

Bosticardo M, Ariotti S, Losana G, Bernabei P, Forni G, Novelli F. Biased activation of human T lymphocytes due to low extracellular pH is antagonized by B7/CD28 costimulation. *Eur J Immunol.* 2001;31:2829-38.

Martin-Fontecha A, Cavallo F, Bellone M, Heltai S, Iezzi G, Tornaghi P, Nabavi N, Forni G, Dellabona P, Casorati G. Heterogeneous effects of B7-1 and B7-2 in the induction of both protective and therapeutic anti-tumor immunity against different mouse tumors. *Eur J Immunol.* 1996;26:1851-9.

Cavallo F, Martin-Fontecha A, Bellone M, Heltai S, Gatti E, Tornaghi P, Freschi M, Forni G, Dellabona P, Casorati G. Co-expression of B7-1 and ICAM-1 on tumors is required for rejection and the establishment of a memory response. *Eur J Immunol.* 1995;25:1154-62.

Pericle F, Liu JH, Diaz JI, Blanchard DK, Wei S, Forni G, Djeu JY. Interleukin-2 prevention of apoptosis in human neutrophils. *Eur J Immunol.* 1994;24:440-4.

Novelli F, Giovarelli M, Gentz R, Zucca M, di Pierro F, Garotta G, Forni G. Modulation of interferon-gamma receptor during human T lymphocyte alloactivation. *Eur J Immunol.* 1993;23:1226-31

Valente G, Ozmen L, Novelli F, Geuna M, Palestro G, Forni G, Garotta G. Distribution of interferon-gamma receptor in human tissues. *Eur J Immunol* 1992;22:2403-2412.

Forni G, Landolfo S, Giovarelli M, Whitmore AC, Herberman RB. Immune recognition of tumor cells in vivo. I. Role of H-2 gene products in T lymphocyte activation against minor histocompatibility antigens displayed by adenocarcinoma cells. *Eur J Immunol.* 1982;12:664-70

Geninatti Crich S, Cabella C, Barge A, Belfiore S, Ghirelli C, Lattuada L, Lanzardo S, Mortillaro A, Tei L, Visigalli M, Forni G, Aime S. In vitro and in vivo magnetic resonance detection of tumor cells by targeting glutamine transporters with Gd-based probes. *J Med Chem* 2006;49:4926-4936

GENE THERAPY (2)

Rovero S, Boggio K, Carlo ED, Amici A, Quaglino E, Porcedda P, Musiani P, Forni G. Insertion of the DNA for the 163-171 peptide of IL1beta enables a DNA vaccine encoding p185(neu) to inhibit mammary carcinogenesis in Her-2/neu transgenic BALB/c mice. *Gene Ther* 2001;8:447-52

De Giovanni C, Nicoletti G, Landuzzi L, Rossi I, Astolfi A, Ricci C, Carlo ED, Musiani P, Forni G, Fradelizi D, Nanni P, Lollini PL. Therapy of lung metastases through combined vaccination with carcinoma cells engineered to release IL-13 and IFN-gamma. *Gene Ther* 2001;8:1698-1704

INTERNATIONAL JOURNAL OF CANCER (15)

Andreasson K, Tegerstedt K, Eriksson M, Curcio C, Cavallo F, Forni G, Dalianis, T, Ramqvist T., Murine pneumotropic virus chimeric Her2/neu virus-like particles as prophylactic and therapeutic vaccines against Her2/neu expressing tumors. *Int J Cancer* 2009;124: 150-156

Gallo P, Dharmapuri S, Nuzzo M, Maldini D, Cipriani B, Forni G, Monaci P. Adenovirus vaccination against neu oncogene exerts long-term protection from tumorigenesis in BALB/neuT transgenic mice. *Int J Cancer* 2007;120:574-584

- Gallo P, Dharmapuri S, Nuzzo M, Maldini D, Iezzi M, Cavallo F, Musiani P, Forni G, Monaci P, Xenogeneic immunization in mice using human ErbB-2DNA delivered by an Adenoviral vector, *Int. J. Cancer* 2004;113:67-77
- Varadhachary A, Wolf JS, Petrak K, O'Malley BW Jr, Spadaro M, Curcio C, Forni G, Pericle F, Oral lactoferrin inhibits growth of established tumors and potentiates conventional chemotherapy. *Int J Cancer* 2004;111,398-403
- Nanni P, Nicoletti G, De Giovanni C, Landuzzi L, Di Carlo E, Iezzi M, Ricci C, Astolfi A, Croci S, Marangoni F, Musiani P, Forni G, Lollini PL. Prevention of HER-2/neu transgenic mammary carcinoma by tamoxifen plus interleukin 12. *Int J Cancer* 2003;105:384-389
- Diodoro MG, Di Carlo E, Zappacosta R, Iezzi M, Coletti A, Modesti A, D'Antuono T, Forni G, Musiani P. Salivary carcinoma in HER-2/neu transgenic male mice: an angiogenic switch is not required for tumor onset and progression. *Int J Cancer*. 2000;88:329-35.
- Nanni P, Pupa SM, Nicoletti G, De Giovanni C, Landuzzi L, Rossi I, Astolfi A, Ricci C, De Vecchi R, Invernizzi AM, Di Carlo E, Musiani P, Forni G, Menard S, Lollini PL. p185(neu) protein is required for tumor and anchorage-independent growth, not for cell proliferation of transgenic mammary carcinoma. *Int J Cancer*. 2000;87:186-94.
- Modesti A, Masuelli L, Modica A, D'Orazi G, Scarpa S, Bosco MC, Forni G. Ultrastructural evidence of the mechanisms responsible for interleukin-4-activated rejection of a spontaneous murine adenocarcinoma. *Int J Cancer*. 1993;53:988-93.
- Roncella S, Ramarli D, Cooper MK, Forni M, Caretto P, Rowe M, Francia di Celle P, Sessarego M, Foa R, Forni G, et al. Establishment of an EBV-positive lymphoblastoid cell line that grows as a lymphoma in nude mice and expresses membrane CD2 molecules. *Int J Cancer* 1990;45:299-307.
- Scarpa S, Dominici C, Grammatico P, Del Porto G, Raschella G, Castello M, Forni G, Modesti A. Establishment and characterization of a human neuroblastoma cell line. *Int J Cancer*. 1989;43:645-51
- Roncella S, Caretto P, Forni G, Cutrona G, Verde A, Ramarli D, di Celle PF, Foa R, Sessarego M, Pistoia V, et al. Studies on the oncogenic potential of Epstein-Barr-virus (EBV)-infected B cells in AIDS-related disorders. *Int J Cancer* 1989;4:78-82.
- Forni G, Giovarelli M, Bosco MC, Caretto P, Modesti A, Boraschi D. Lymphokine-activated tumor inhibition: combinatory activity of a synthetic nonapeptide from interleukin-1, interleukin-2, interleukin-4, and interferon-gamma injected around tumor-draining lymph nodes. *Int J Cancer* 1989;4s:62-5

Giovarelli M, Cofano F, Vecchi A, Forni M, Landolfo S, Forni G. Interferon-activated tumor inhibition in vivo. Small amounts of interferon-gamma inhibit tumor growth by eliciting host systemic immunoreactivity. *Int J Cancer*. 1986;37:141-8

Forni G, Giovarelli M, Lanfrancone L, Varesio L. Suppressor macrophages in tumor-bearing mice. Inconsistency between in vivo and in vitro findings? *Int J Cancer*. 1982;29:695-8

Comoglio PM, Forni G. Plasma-cell and tumor-associated membrane antigens of mouse plasmacytoma MOPC-315 and MOPC-460. *Int J Cancer*. 1973, 15;12:613-625

BRITISH JOURNAL OF HAEMATOLOGY

Foa R, Caretto P, Fierro MT, Bonferroni M, Cardona S, Guarini A, Lista P, Pegoraro L, Mandelli F, Forni G, et al. Interleukin 2 does not promote the in vitro and in vivo proliferation and growth of human acute leukaemia cells of myeloid and lymphoid origin. *Br J Haematol* 1990;75:34-40

JOURNAL OF CELL PHYSIOLOGY

Novelli F, Allione A, Wells V, Forni G, Mallucci L. Negative cell cycle control of human T cells by beta-galactoside binding protein (beta GBP): induction of programmed cell death in leukaemic cells. *J Cell Physiol*. 1999;178:102-8

LABORATORY INVESTIGATION (2)

Di Carlo E, Diodoro MG, Boggio K, Modesti A, Modesti M, Nanni P, Forni G, Musiani P. Analysis of mammary carcinoma onset and progression in HER-2/neu oncogene transgenic mice reveals a lobular origin. *Lab Invest*. 1999, 79:1261-1269

Musiani P, Allione A, Modica A, Lollini PL, Giovarelli M, Cavallo F, Belardelli F, Forni G, Modesti A. Role of neutrophils and lymphocytes in inhibition of a mouse mammary adenocarcinoma engineered to release IL-2, IL-4, IL-7, IL-10, IFN-alpha, IFN-gamma, and TNF-alpha. *Lab Invest*. 1996;74:146-57

BRITISH JOURNAL OF CANCER (7)

Berta GN, Mognetti B, Spadaro M, Trione E, Corvetti G, Amici A, Forni G, Di Carlo F Cavallo F, Anti HER-2 DNA vaccine protects Syrian hamsters against squamous cell carcinomas, *Br J Cancer* 2005;93:1250-1256

Milella M, Jacobelli J, Cavallo F, Guarini A, Velotti F, Frati L, Foa R, Forni G, Santoni A. Interleukin-2 gene transfer into human transitional cell carcinoma of the urinary bladder. *Br J Cancer*. 1999;79:770-9

Nanni P, De Giovanni C, Landuzzi L, Nicoletti G, Frabetti F, Rossi I, Cavallo F, Giovarelli M, Forni G, Lollini PL. Therapy of murine mammary carcinoma metastasis with interferon gamma and MHC gene-transduced

tumour cells. Br J Cancer. 1996;74:1564-9

Cortesina G, De Stefani A, Galeazzi E, Cavallo GP, Badellino F, Margarino G, Jemma C, Forni G. Temporary regression of recurrent squamous cell carcinoma of the head and neck is achieved with a low but not with a high dose of recombinant interleukin 2 injected perilymphatically. Br J Cancer. 1994;69:572-6

Giovarelli M, Comoglio PM, Forni G. Induction of resistance or enhancement to a transplantable murine plasmacytoma by transfer of non-immune leucocytes. Br J Cancer. 1976;34:233-8

Forni G, Comoglio PM. Effect of solubilized membrane antigens and tumour bearer serum on tumour growth in syngeneic hosts. Br J Cancer. 1974;30:365-369

Forni G, Comoglio PM. Growth of syngeneic tumours in unimmunized newborn and adult hosts. Br J Cancer. 1973;27:120-127

JOURNAL OF LEUKOCYTE BIOLOGY (4)

Cappello P, Caorsi C, Bosticardo M, De Angelis S, Novelli F, Forni G, Giovarelli M, CCL16/LEC chemokine powerfully triggers effector and antigen presenting functions of macrophages and enhances T cell cytotoxicity, J. Leuk. Biol 2004;75: 135-147

Losana G, Bovolenta C, Rigamonti L, Borghi I, Altare F, Jouanguy E, Forni G, Casanova JL, Sherry B, Mengozzi M, Trinchieri G, Poli G, Gerosa, F, Novelli F. IFN-gamma and IL-12 differentially regulate CC-chemokine secretion and CCR5 expression in human T lymphocytes. J Leukocyte Biol 2002 72:735-42
Bernabei P, Coccia EM, Rigamonti L, Bosticardo M, Forni G, Pestka S, Krause CD, Battistini A, Novelli F. Interferon-gamma receptor 2 expression as the deciding factor in human T, B, and myeloid cell proliferation or death. J Leukoc Biol. 2001;70:950-60

Musso T, Bosco MC, Longo DL, Espinoza-Delgado I, Sica A, Cox GW, Gusella GL, Forni G, Varesio L. LPS-inducible nuclear factor in human monocytes that binds the negative regulatory element of the HIV LTR. J Leukocyte Biol. 1994;56:21-6

INFECTION AND IMMUNITY

Cuffini A, Carlone NA, Forni G. Bacterial phagocytosis by macrophages from lipopolysaccharide responder and nonresponder mouse strains. Infect Immun. 1980;28:762-5

HUMAN GENE THERAPY (4)

Rolla S, Marchini C, Malinarich S, Quaglino E, Lanzardo S, Montani M, Angeletti M, Ramadori G, Forni G, Cavallo F, Amici A, Protective immunity against neu+ carcinomas elicited by electroporation of plasmids coding for decreasing fragments of rat neu extracellular domain, Human Gene Ther 2008;19:229-24

Cipriani B, Fridman A, Bendtsen C, Dharmapuri S, Mennuni C, Pak I, Mesiti G, Forni G, Monaci P, Bagchi A, Ciliberto G, La Monica N, Scarselli E. Therapeutic vaccination halts disease progression in BALB-neuT mice: the amplitude of elicited immune response is predictive of vaccine efficacy. *Hum Gene Ther.* 2008;19:670-680

Nanni P, De Giovanni C, Nicoletti G, Landuzzi L, Rossi I, Frabetti F, Giovarelli M, Forni G, Cavallo F, Di Carlo E, Musiani P, Lollini PL. The immune response elicited by mammary adenocarcinoma cells transduced with interferon-gamma and cytosine deaminase genes cures lung metastases by parental cells. *Hum Gene Ther.* 1998;9:217-24

Lollini PL, De Giovanni C, Landuzzi L, Nicoletti G, Frabetti F, Cavallo F, Giovarelli M, Forni G, Modica A, Modesti A. Transduction of genes coding for a histocompatibility (MHC) antigen and for its physiological inducer interferon-gamma in the same cell: efficient MHC expression and inhibition of tumor and metastasis growth. *Hum Gene Ther.* 1995;6:743-52

PHARMACOLOGICAL RESEARCH (2)

Cortesina G, De Stefani A, Galeazzi E, Cavallo GP, Bussi M, Giordano C, Forni G. Interleukin-2 and head and neck squamous cell carcinoma: clinical and pathological studies. *Pharmacol Res.* 1992;26S2:50-1

Cavallo F, Gulino A, Stoppacciaro A, Giovarelli M, Forni G. From exogenous cytokines to gene therapy: cytokine activated tumor inhibition. *Pharmacol Res.* 1992;26S2:48-9

CANCER IMMUNOLOGY IMMUNOTHERAPY (7)

Cavallo F, De Giovanni C, Nanni P, Forni G, Lollini PL, 2011: The immune hallmarks of cancer, *Cancer Immunol Immunother*, 2011;60:319-326

Masuelli L, Marzocchella L, Focaccetti C, Lista F, Nardi A, Scardino A, Mattei M, Turriziani M, Modesti M, Forni G, Schlom J, Modesti M, Bei R, Local delivery of recombinant vaccinia virus encoding for neu counteracts growth of mammary tumors more efficiently than systemic delivery in neu transgenic mice, *Cancer Immunol Immunother*, 2010;59:1247-1258

Park JM, Terabe M, Donaldson DD, Forni G, Berzofsky J.A., Natural immunosurveillance against spontaneous, autochthonous breast cancers revealed and enhanced by blockade of IL-13-mediated negative regulation, *Cancer Immunol Immunother* 2008;57:907-912

Calogero RA, Quagliano E, Saviozzi S, Forni G, Cavallo F, Oncoantigens as anti-tumor vaccination targets: The chance of a lucky strike?, *Cancer Immunol Immunother*, 2008;57:1685-1694

Astolfi A, Rolla S, Nanni P, Quaglino E, De Giovanni C, Iezzi M, Musiani P, Forni G, Lollini P-L, Cavallo F, Calogero R, Immune prevention of mammary carcinogenesis HER-2/neu transgenic mice: A microarray scenario, *Cancer Immunol Immunoter* 2005;54:599-610

Spadaro M, Lanzardo S, Curcio C, Forni G and Cavallo F, Immunological inhibition of carcinogenesis, *Cancer Immunol Immunoter*, 2004;53:204-126

Lollini P-L, Forni G Antitumor vaccines: Is it possible to prevent a tumor?, *Cancer Immunol. Immunother* 2002;51:409-416

Forni G, Bindoni M, Santoni A, Giovarelli M, Mantovani A. Physiological and pathological influences of central nervous system on the immune system: a critical appraisal. *J Psychiatr Res.* 1984;18:491-9

TRANSPLANTATION (4)

Giovarelli M, Landolfo S, Scher I, Forni G. Distinct alloantigens trigger proliferative or nonproliferative T lymphocyte activation in CBA/N, CBA/J, and C3H mice. *Transplantation.* 1982;33:260-264

Landolfo S, Giovarelli M, Forni G. Alloantigen requirements for nonproliferative activation of T lymphocytes. *Transplantation.* 1979;27:290-291

Forni G, Varesio L, Giovarelli M, Landolfo S. Source of tumor cells influences their immune recognition by H-2-matched mice. *Transplantation.* 1979;27:433-435

Landolfo S, Marcucci F, Giovarelli M, Forni G. Does macrophage production of interferon after alloantigen stimulation depend on factors from activated T lymphocytes? *Transplantation.* 1980;29:87-89

BMC BIONFORMATICS (2)

Cavallo F, Astolfi A, Iezzi M, Cordero F, Lollini PL, Forni G, Calogero R. An integrated approach of immunogenomics and bioinformatics to identify new Tumor Associated Antigens (TAA) for mammary cancer immunological prevention. *BMC Bioinformatics.* 2005;6,S4:S7

VACCINE (2)

Quaglino E, Mastini C, Iezzi M, Forni G, Musiani P, Klapper LN, Hardy B, Cavallo F, The adjuvant activity of BAT antibody enables DNA vaccination to inhibit the progression of established autochthonous Her-2/neu carcinomas in BALB/c mice, *Vaccine* 2005;23:3280-3287

Cruz JS, Lau SY, Ramirez EM, Giovanni CD, Forni G, Morrison SL, Penichet ML. Protein vaccination with the HER2/neu extracellular domain plus anti-HER2/neu antibody-cytokine fusion proteins induces a protective anti-HER2/neu immune response in mice. *Vaccine* 2003 21:1317-132

Other journals

Bandini S, Macagno M, Hysi A, Lanzardo S, Conti L, Bello A, Riccardo F, Ruiu R, Merighi IF, Forni G, Iezzi M, Quaglino E, Cavallo F. The non-inflammatory role of C1q during Her2/neu-driven mammary carcinogenesis. *Oncoimmunology*. 2016 8; e1253653.

Barutello G, Curcio C, Spadaro M, Arigoni M, Trovato R, Bolli E, Zheng Y, Ria F, Quaglino E, Iezzi M, Riccardo F, Holmgren L, Forni G, Cavallo F. Antitumor immunization of mothers delays tumor development in cancer-prone offspring. *Oncoimmunology*. 2015,4:e1005500.

Forni G. Vaccines for tumor prevention: a pipe dream? *J Infect Dev Ctries*. 2015,9:600-8.

Bandini S, Curcio C, Macagno M, Quaglino E, Arigoni M, Lanzardo S, Hysi A, Barutello G, Consolino L, Longo DL, Musiani P, Forni G, Iezzi M, Cavallo F. Early onset and enhanced growth of autochthonous mammary carcinomas in C3-deficient Her2/neu transgenic mice. *Oncoimmunology*. 2013:e26137.

Spadaro M, Montone M, Arigoni M, Cantarella D, Forni G, Pericle F, Pascolo S, Calogero RA, Cavallo F. Recombinant human lactoferrin induces human and mouse dendritic cell maturation via Toll-like receptors 2 and 4. *FASEB J*. 2014,28:416-29. 24088817.

Conti L, Lanzardo S, Iezzi M, Montone M, Bolli E, Brioschi C, Maiocchi A, Forni G, Cavallo F. Optical imaging detection of microscopic mammary cancer in ErbB-2 transgenic mice through the DA364 probe binding $\alpha v \beta 3$ integrins. *Contrast Media Mol Imaging*. 2013,8:350-60.

Iezzi M, Quaglino E, Amici A, Lollini PL, Forni G, Cavallo F. DNA vaccination against oncoantigens: A promise. *Oncoimmunology*. 2012,1:316-325.

Lanzardo S, Conti L, Brioschi C, Bartolomeo MP, Arosio D, Belvisi L, Manzoni L, Maiocchi A, Maisano F, Forni G, A new optical imaging probe targeting $\alpha v \beta 3$ integrin in glioblastoma xenografts, *Contrast Media and Molecular Imaging*, 2011,6:449-58.

Sarah Zohar S, Baldi I, Forni G, Merletti F, Masucci G, Gregori D, Planning a Bayesian early-phase phase I/II study for human vaccines in HER2 carcinomas, *Pharmaceutical Statistics*, 2011; 10:218-226

Bolli E, Quaglino E, Arigoni M, Lollini PL, Calogero R, Forni G, Cavallo F, Oncoantigens for an immune prevention of cancer, *Am J Cancer Res* 2011;1:255-264

De Santis R, Leoni B, Rosi A, Albertoni C, Forni G, Cojoca R, Iezzi M, Musiani P, Paganelli G, Chinol M, Carminati P, AvidinOX™ for Avidin for Highly Efficient Tissue pre-targeted Radionuclide Therapy, *Cancer Biotherapy & Radiopharmaceuticals*, 2010;25:143-148

Barbieri I, Quaglino E, Maritano D, Pannellini T, Riera L, Cavallo F, Forni G, Musiani P, Chiarle R, Poli V. Stat3 is required for anchorage-independent growth and metastasis but not for mammary tumor development downstream of the ErbB-2 oncogene. *Molecular Carcinogenesis*, 49:114-120, 2010

Masucci GV, Andersson E, Villabona L, Helgadóttir H, Bergfeld K, Cavallo F, Forni G, Ferrone S, Aniruddha C, Kiessling R, Seliger B and Kiessling R, Survival of the fittest or best adapted– HLA-dependent tumour development, *J Nucleic Acids Invest*, 1:e9,2010

Cavallo F, Forni G. Recents avances in cancer immunotherapy with an emphasis on vaccines. *Expert Rev Vaccines*. 2009 8: 25-28.

Quaglino E, Mastini C, Forni G, Cavallo F. ErbB2 transgenic mice: a tool for investigation of the immune prevention and treatment of mammary carcinomas. *Curr Protoc Immunol*. 2008;Chapter 20:Unit 20.9.1-20.9-10.

Caorsi C, Cappello P, Ceruti P, Amici A, Marchini C, Novelli F, Forni G, Giovarelli M. CCL16 enhances the CD8+ and CD4+ T cell reactivity to human HER-2 elicited by dendritic cells loaded with rat ortholog HER-2, *Int J Immunopathol Pharmacol*. 2008;21:867-877

Lo Iacono M, Cavallo F, Quaglino E, Rolla S, Iezzi M, Pupa SM, De Giovanni C, Lollini PL, Musiani P, Forni G, Calogero RA. A limited autoimmunity to p185neu elicited by DNA and allogeneic cell vaccine hampers the progression of preneoplastic lesions in HER-2/NEU transgenic mice. *Int J Immunopathol Pharmacol*. 2005;18:351-363

Lollini PL, De Giovanni C, Pannellini T, Cavallo F, Forni G, Nanni P. Cancer immunoprevention. *Future Oncol*. 2005:57-66

Calogero RA, Musiani P, Forni G, Cavallo F, Towards a long-lasting prevention of Her2 mammary carcinomas. *Directions from transgenic mice. Cell Cycle* 2004;3:704-706

Di Carlo E, Forni G, Musiani P. Neutrophils in the antitumoral immune response. *Chem Immunol Allergy*. 2003;83:182-203

Giovarelli M, Landolfo S, Whitmore AC, Forni G. Rous sarcoma virus-induced tumors in mice-I. Macrophage-mediated natural cytotoxicity. *Eur J Cancer Clin Oncol*. 1982;18:307-15

Forni G, Curcio C, Spadaro M, Iliffe J, Quaglino E, Di Carlo E, Musiani P, Lollini PL. Immunization in tumor prevention. *Int Immunopharmacol*. 2003;3:1151-1158.

Cavallo F, Forni G. Recents avances in cancer immunotherapy with an emphasis on vaccines. *Expert Rev Vaccines* 2009 8: 25-28

Cappello P, Novelli F, Forni G, Giovarelli M. Death receptor ligands in tumors. *J Immunother*. 2002;25:1-15.

Di Carlo E, Coletti A, Modesti A, Giovarelli M, Forni G, Musiani P. Local release of interleukin-10 by transfected mouse adenocarcinoma cells exhibits pro-and anti-inflammatory activity and results in a delayed tumor rejection. *Eur Cytokine Netw.* 1998;9:61-68.

Forni G, Boggio K, Giovarelli M, Cavallo F. The dream of effective cytokine-based tumor vaccines. *Eur Cytokine Netw.* 1997;8:324-325

Forni G, Cavallo F, Consalvo M, Allione A, Dellabona P, Casorati G, Giovarelli M. Molecular approaches to cancer immunotherapy. *Cytokines Mol Ther.* 1995;1:225-248

Cavallo F, Giovarelli M, Gulino A, Vacca A, Scala G, Forni G. Interleukin-induced tumor immunogenicity. *Immunol Ser.* 1994;61:183-93

Forni G, Giovarelli M, Cavallo F, Consalvo M, Allione A, Modesti A, Musiani P, Colombo MP. Cytokine-induced tumor immunogenicity: from exogenous cytokines to gene therapy. *J Immunother* 1993;14:253-257

Di Pierro F, Cavallo F, Pericle F, Bertini S, Giovarelli M, Forni G. Strategies for cytokine utilisation in tumor therapy. *Med Oncol Tumor Pharmacother.* 1993;10:53-59

Jemma C, Giovarelli M, Vai S, Cavallo F, Forni G. In vitro and in vivo immunomodulatory activity of ST 789 on two human lymphoblastic T cell lines. *Thymus.* 1992;19 S1:79-87

Cavallo F, Riccardi C, Forni M, Pericle F, Bosco MC, Giovarelli M, Soleti A, Forni G. Growth and dissemination of human malignant lymphoblasts in immunosuppressed nu/nu mice. *Nat Immun Cell Growth Regul.* 1991;10:256-64

Valente G, De Stefani A, Jemma C, Giovarelli M, Geuna M, Cortesina G, Forni G, Palestro G. Infiltrating leukocyte populations and T-lymphocyte subsets in head and neck squamous cell carcinomas from patients receiving perilymphatic injections of recombinant interleukin 2. A pathologic and immunophenotypic study. *Mod Pathol.* 1990;3:702-708

Musiani P, De Campora E, Valitutti S, Castellino F, Calearo C, Cortesina G, Giovarelli M, Jemma C, De Stefani A, Forni G. Effect of low doses of interleukin-2 injected perilymphatically and peritumorally in patients with advanced primary head and neck squamous cell carcinoma. *J Biol Response Mod.* 1989;8:571-578

Fontana G, Caccia P, Alladio F, Laudi M, Pigato M, Sesia G, Forni G, Giovarelli M. Interferon-gamma in the treatment of superficial and recurrent bladder carcinoma. Phase one study. *Prog Clin Biol Res.* 1989;303:479-80

Giovarelli M, Foa R, Benetton G, Lusso P, Fierro MT, Forni G. Release of interleukin-2-like material by B-chronic lymphocytic leukemia cells. An autocrine or paracrine model of production and utilization? *Leuk Res.* 1988;12:201-209

Foa R, Giovarelli M, Fierro MT, Bonferroni M, Forni G. Autocrine or paracrine models of cytokine production and utilization in B-cell chronic lymphocytic leukaemia. *Nouv Rev Fr Hematol.* 1988;30:339-341

Forni G, Cavallo GP, Giovarelli M, Benetton G, Jemma C, Barioglio MG, De Stefani A, Forni M, Santoni A, Modesti A, et al. Tumor immunotherapy by local injection of interleukin 2 and non-reactive lymphocytes. Experimental and clinical results. *Prog Exp Tumor Res.* 1988;32:187-212

Giovarelli M, Arione R, Jemma C, Musso T, Benetton G, Forni G, Cornaglia-Ferraris P. In vitro and in vivo immunomodulatory activity of an N-9 arginyl hypoxanthine derivative (PCF-39). *Int J Immunopharmacol.* 1987;9:659-667

Forni G, Musso T, Santoni A, Giovarelli M. Local administration of interleukin-2 activates lymphocytes from tumor bearing mice to recruit host immunoreactivity and inhibit tumor growth. *Prog Clin Biol Res.* 1987;244:105-114

Santoni A, Cerruti Sola S, Giovarelli M, Martinetto P, Vietti D, Forni G. Modulation of natural killer activity in mice by prolonged administration of various doses of dietary retinoids. *Nat Immun Cell Growth Regul.* 1986;5:259-266

Giovarelli M, Landolfo S, Whitmore AC, Forni G. Rous sarcoma virus-induced tumors in mice--I. Macrophage-mediated natural cytotoxicity. *Eur J Cancer Clin Oncol.* 1982;18:307-315

Varesio L, Landolfo S, Giovarelli M, Forni G. The macrophage as the social interconnection within the immune system. *Dev Comp Immunol.* 1980;4:11-19

Cavallo G, Giovarelli M, Forni G, Landolfo S. Is antibody-dependent cellular cytotoxicity an important mechanism of resistance to tumors in vivo? *Immunochemistry.* 1978;15:801-805